C

Concord Biotech Ltd
NSE:CONCORDBIO

Watchlist Manager
Concord Biotech Ltd
NSE:CONCORDBIO
Watchlist
Price: 2 151.05 INR 0.71% Market Closed
Market Cap: 225B INR
Have any thoughts about
Concord Biotech Ltd?
Write Note
Section:
 

Relative Value

The Relative Value of one CONCORDBIO stock under the Base Case scenario is 1 479.83 INR. Compared to the current market price of 2 151.05 INR, Concord Biotech Ltd is Overvalued by 31%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CONCORDBIO Relative Value
Base Case
1 479.83 INR
Overvaluation 31%
Relative Value
Price
C
Worst Case
Base Case
Best Case

Valuation Multiples

20.7
P/S
P/S
Price to Sales
20.7
vs History
0
vs Industry
10
Median 3Y
15.2
Median 5Y
15.2
Industry
2.5
Forward
18
More Details
68.6
P/E
P/E
Price to Earnings
68.6
vs History
0
vs Industry
7
Median 3Y
50.1
Median 5Y
50.1
Industry
21.8
Forward
58.2
More Details
84.8
P/OCF
P/OCF
Price to OCF
84.8
vs History
0
vs Industry
6
Median 3Y
62.3
Median 5Y
62.3
Industry
16.1
More Details
148.7
P/FCFE
P/FCFE
Price to FCFE
148.7
vs History
41
vs Industry
5
Median 3Y
140.6
Median 5Y
140.6
Industry
23.8
More Details
14.1
P/B
P/B
Price to Book Value
14.1
vs History
0
vs Industry
6
Median 3Y
11.1
Median 5Y
11.1
Industry
2.1
More Details
20.4
EV/S
EV/S
Enterprise Value to Sales
20.4
vs History
0
vs Industry
9
Median 3Y
14.9
Median 5Y
14.9
Industry
2.7
Forward
17.7
More Details
26.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
26.9
vs History
0
vs Industry
8
Median 3Y
20.1
Median 5Y
20.1
Industry
5.2
More Details
48.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
48.4
vs History
5
vs Industry
8
Median 3Y
35.5
Median 5Y
35.5
Industry
13.5
Forward
43
More Details
54.9
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
54.9
vs History
0
vs Industry
9
Median 3Y
40.1
Median 5Y
40.1
Industry
16.8
Forward
48.6
More Details
83.6
EV/OCF
EV/OCF
Enterprise Value to OCF
83.6
vs History
0
vs Industry
6
Median 3Y
61.4
Median 5Y
61.4
Industry
15.2
More Details
123.4
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
123.4
vs History
23
vs Industry
4
Median 3Y
107.4
Median 5Y
107.4
Industry
19.3
More Details
16.3
EV/IC
EV/IC
Enterprise Value to IC
16.3
vs History
0
vs Industry
9
Median 3Y
12.3
Median 5Y
12.3
Industry
1.9
More Details

Multiples Across Competitors

CONCORDBIO Competitors Multiples
Concord Biotech Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Concord Biotech Ltd
NSE:CONCORDBIO
225B INR 20.7 68.6 48.4 54.9
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
756.2B USD 18.5 90.3 48.5 54.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 10.2 29 20.2 23
US
Johnson & Johnson
NYSE:JNJ
350.6B USD 4 23.9 11.6 15
US
Merck & Co Inc
NYSE:MRK
252B USD 4 20.7 10.5 12.6
CH
Roche Holding AG
SIX:ROG
200.1B CHF 3.4 17.4 9.8 11.6
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP 4.1 31.5 169.4 253.8
CH
Novartis AG
SIX:NOVN
171.5B CHF 3.8 10.8 9.4 13.1
US
Pfizer Inc
NYSE:PFE
151.5B USD 2.5 35.6 10.6 16
P/S Multiple
Revenue Growth P/S to Growth
IN
C
Concord Biotech Ltd
NSE:CONCORDBIO
Average P/S: 382 943.9
20.7
86%
0.2
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
22%
194 879.4
US
Eli Lilly and Co
NYSE:LLY
18.5
109%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
29%
19.9
DK
Novo Nordisk A/S
CSE:NOVO B
10.2
77%
0.1
US
Johnson & Johnson
NYSE:JNJ
4
13%
0.3
US
Merck & Co Inc
NYSE:MRK
4
20%
0.2
CH
Roche Holding AG
SIX:ROG
3.4
15%
0.2
UK
AstraZeneca PLC
LSE:AZN
4.1
35%
0.1
CH
Novartis AG
SIX:NOVN
3.8
17%
0.2
US
Pfizer Inc
NYSE:PFE
2.5
10%
0.3
P/E Multiple
Earnings Growth P/E to Growth
IN
C
Concord Biotech Ltd
NSE:CONCORDBIO
Average P/E: 36.4
68.6
110%
0.6
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
90.3
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.9
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.7
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.4
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31.5
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.6
719%
0
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
C
Concord Biotech Ltd
NSE:CONCORDBIO
Average EV/EBITDA: 418.5
48.4
97%
0.5
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.5
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.6
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.5
331%
0
CH
Roche Holding AG
SIX:ROG
9.8
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.4
64%
2.7
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.6
31%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
C
Concord Biotech Ltd
NSE:CONCORDBIO
Average EV/EBIT: 1 815.7
54.9
113%
0.5
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.2
211%
0.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
23
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
15
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.6
675%
0
CH
Roche Holding AG
SIX:ROG
11.6
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.8
131%
1.9
CH
Novartis AG
SIX:NOVN
13.1
58%
0.2
US
Pfizer Inc
NYSE:PFE
16
68%
0.2

See Also

Summary
CONCORDBIO intrinsic value, competitors valuation, and company profile.
DCF Valuation
CONCORDBIO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CONCORDBIO stock valuation using valuation multiples.
Wall Street Estimates
CONCORDBIO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CONCORDBIO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 210,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.